BETA
Israeli medical device developer building image-guided ultrasound ablation technology, with renal-denervation and atrial-fibrillation development programmes.
Healium Medical is a Yokneam, Israel medical device company founded in 2017 and led by co-founder and CEO Ran Sela. It develops miniature transcatheter ultrasound technology intended to combine therapeutic energy delivery with real-time imaging and tissue monitoring.
Its Echomplish platform combines a catheter, control hardware and procedure software. The dual-mode ultrasound approach is designed to create lesions without direct tissue contact while providing information about anatomy and treatment progress. The company’s current homepage highlights Echomplish RDN for renal denervation, an approach being developed for hypertension treatment.
Healium has also pursued atrial-fibrillation ablation through its EU-funded DMUT programme. That project reported animal-study results and engineering development through August 2025. The platform remains in development, with the renal-denervation and atrial-fibrillation applications requiring their own clinical and regulatory evaluation.
Echomplish is presented as a development-stage ultrasound ablation platform. Healium’s current materials highlight renal denervation for hypertension, while its EU-funded DMUT programme investigated atrial-fibrillation ablation. Evidence from one application should not be treated as validation or authorization of the other. [3][8][2]
The DMUT report covering September 2024 through August 2025 describes catheter and software development, acoustic measurements from more than 100 lesion points in animal studies, and circumferential pulmonary-vein ablation in an animal model. It identifies further procedure development, chronic evidence and financing as requirements before clinical studies. These are preclinical findings rather than demonstrated patient outcomes. [2]
Latest recorded source review: 2026-11-04.
Scope: selected product families.
No commercially marketed product portfolio has been established in the reviewed material.
Development-stage platform combining a miniature ultrasound catheter, control hardware and procedure software for imaging-guided energy delivery and tissue monitoring. Current company materials highlight a renal-denervation configuration; atrial-fibrillation ablation has been investigated in its preclinical DMUT programme. [7][8][6][2]
In development · Image-guided ultrasound ablationFinal-period report describes preclinical ablation and system development, with further evidence and financing required before clinical studies. [2]
CORDIS records a €2.5 million EU contribution to the DMUT project. [1]
Company reports winning the ICI 2019 competition and receiving a US$100,000 prize from the Jon DeHaan Foundation. [3]
Company established in Israel to develop transcatheter ultrasound technology. [9]
Accessed 11/04/2026
Last substantive review: 11/4/2026